Friedreich's Ataxia
Neurology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AmgenTHOUSAND OAKS, CA
2 programs2
Interferon γ-1bPhase 31 trial
interferon γ-1bPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Amgeninterferon γ-1b
AmgenInterferon γ-1b
Alliance PharmaceuticalsEPI-743
Clinical Trials (3)
Total enrollment: 128 patients across 3 trials
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Start: Jun 2016Est. completion: Mar 201738 patients
Phase 3Completed
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Start: Dec 2015Est. completion: Mar 201786 patients
Phase 3Completed
EPI-743 in Friedreich's Ataxia Point Mutations
Start: Oct 2013Est. completion: Jun 20164 patients
Phase 2Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
9h ago
Director of Finance
CoMind
London, UK
9h ago
Electronics Engineering Manager
CoMind
London, UK
9h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space